Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus almonertinib as neoadjuvant therapy followed by adjuvant almonertinib in resectable EGFR-mutant non-small cell lung cancer
ChiCTR2500102344Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan and almonertinib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: pathological complete response and major pathological response. Planned start May 2025; status: not yet recruiting.
02
Drugs
izalontamab brengitecanalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102344.